Marc-Olivier Turgeon PhD
Senior Associate
Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience. The company is committed to rapidly advancing its innovative, precision-targeted therapeutics.
Engrail applies precision chemistry and pharmacology to develop transformative medicines for patients who have been underserved by existing treatments.
The company's approach centers on scientifically validated mechanisms of action with established proof of concept. This improves the probability of success in rapidly delivering best-in-class therapies to patients in need.
Industry
Biotech
Status
Current
Location
US
